FORTREA HOLDINGS DL-,001 Aktie Logo
US34965K1079
A3ECGB
FTRE

FORTREA HOLDINGS DL-,001 Aktie

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 21,33 € (+19,16 %). La médiane est de 21,38 € (+19,44 %).

Acheter
  7
Conserver
  5
Vendre
  1

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia

    Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » Plus sur finanzen.net


  • Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business

    Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » Plus sur finanzen.net


  • Fortrea buys early-phase unit from Worldwide for $45 million

    Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Plus sur de.investing.com


  • Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials

    Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Plus sur finanzen.net


  • Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials

    Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, FORTREA HOLDINGS DL-,001 Aktie a réalisé un chiffre d'affaires de 610,49 M € et un bénéfice net de 529,71 k €
(EUR) septembre 2026
YoY
Chiffre d'affaires 610,49 M 2,16 %
Bénéfice brut 123,16 M 40,18 %
Bénéfice net 529,71 k 103,91 %
EBITDA 32,31 M 180,88 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
1,69 Md €
Nombre d'actions
94,6 M
Plus haut/bas sur 52 semaines
23,80 € - 7,78 €
Dividendes Non
Bêta
1,86
Ratio P/E
-25,99
Ratio PEG
-0,11
Ratio P/B
3,52
Ratio P/S
0,69

Profil de l'entreprise

Fortrea Holdings Inc. fournit des solutions de développement clinique et d'accès des patients au secteur des sciences de la vie. Elle propose la gestion d'essais cliniques de phases I à IV, la pharmacologie clinique, des solutions d'essais différenciées reposant sur la technologie, ainsi que des services post-approbation. L'entreprise dessert les organisations pharmaceutiques, biotechnologiques et de dispositifs médicaux. Fortrea Holdings Inc. a son siège à Durham, en Caroline du Nord.

Nom
FORTREA HOLDINGS DL-,001 Aktie
PDG
Anshul Thakral
Siège social Durham, nc
États-Unis
Site web
Industrie
Équipements et fournitures médicaux
Introduction en bourse
20/06/2023
Employés 14 000

Symboles boursiers

Bourse Symbole
NASDAQ
FTRE
Frankfurt
K67.F
Düsseldorf
K67.DU
München
K67.MU
🍪

Parqet  utilise des cookies. En savoir plus